Arcus Retains Casdatifan, Announces $150M Stock Offering
18 Feb 2025 //
BUSINESSWIRE
Data Demonstrated Best-in-Class Potential for Casdatifan In Kidney Cancer
18 Feb 2025 //
BUSINESSWIRE
18 Feb 2025 //
BUSINESSWIRE
18 Feb 2025 //
BUSINESSWIRE